Eton Pharmaceuticals Inc (ETON) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Eton Pharmaceuticals Inc stock (ETON) is currently trading at $23.84. Eton Pharmaceuticals Inc PS ratio (Price-to-Sales) is 7.49. Analyst consensus price target for ETON is $39.33. WallStSmart rates ETON as Sell.
- ETON PE ratio analysis and historical PE chart
- ETON PS ratio (Price-to-Sales) history and trend
- ETON intrinsic value — DCF, Graham Number, EPV models
- ETON stock price prediction 2025 2026 2027 2028 2029 2030
- ETON fair value vs current price
- ETON insider transactions and insider buying
- Is ETON undervalued or overvalued?
- Eton Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ETON Piotroski F-Score and Altman Z-Score
- ETON analyst price target and Smart Rating
Eton Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Eton Pharmaceuticals Inc (ETON) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Eton Pharmaceuticals Inc (ETON) Key Strengths (3)
Revenue surging 82.70% year-over-year
Strong operational efficiency: $21 kept per $100 revenue
58.71% held by institutions, strong professional interest
Supporting Valuation Data
Eton Pharmaceuticals Inc (ETON) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -12.60%, profits shrinking
Company is losing money with a negative profit margin
Very expensive at 25.8x book value
Premium valuation at 7.5x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Eton Pharmaceuticals Inc (ETON) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Operating Margin, Institutional Own.. Profitability is solid with Operating Margin at 21.00%. Growth metrics are encouraging with Revenue Growth at 82.70%.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Sales (7.49), Price/Book (25.84) suggest expensive pricing. Growth concerns include EPS Growth at -12.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -18.20%, Profit Margin at -5.76%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -18.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 82.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ETON Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ETON's Price-to-Sales ratio of 7.49x trades at a deep discount to its historical average of 700.3x (51th percentile). The current valuation is 100% below its historical high of 6133.64x set in Jan 2021, and 190% above its historical low of 2.58x in Sep 2022. Over the past 12 months, the PS ratio has compressed from ~9.0x as trailing revenue scaled faster than the stock price.
Compare ETON with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Eton Pharmaceuticals Inc (ETON) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Eton Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 80M with 83% growth year-over-year. The company is currently unprofitable, posting a -5.8% profit margin.
Key Findings
Revenue growing at 83% YoY, reaching 80M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
The company is unprofitable with a -5.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Eton Pharmaceuticals Inc maintain 83%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Eton Pharmaceuticals Inc.
Bottom Line
Eton Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 83% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -5.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Eton Pharmaceuticals Inc(ETON)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.